Equities researchers at Citigroup assumed coverage on shares of Warner Chilcott (NASDAQ: WCRX) in a report issued on Friday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating on the stock.
The analysts wrote, “While we acknowledge that the valuation of WCRX is materially lower than that of its peer group, at a 2014e earnings multiple of 4x vs. the sector average of 14x, we forecast a negative 5-year overall revenue CAGR of -5% vs. the peer group average of +7%. We prefer to remain on the sidelines pending execution on business development activities that could contribute to the company’s longer term growth profile.”
Warner Chilcott (NASDAQ: WCRX) opened at 13.51 on Friday. Warner Chilcott has a 52-week low of $10.85 and a 52-week high of $23.28. The stock’s 50-day moving average is currently $13.6. The company has a market cap of $3.385 billion and a price-to-earnings ratio of 8.39.
Warner Chilcott (NASDAQ: WCRX) last posted its quarterly earnings results on Friday, February 22nd. The company reported $0.50 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.73 by $0.23. The company had revenue of $612.00 million for the quarter, compared to the consensus estimate of $565.21 million. During the same quarter last year, the company posted $0.95 earnings per share. Warner Chilcott’s revenue was down 5.3% compared to the same quarter last year. On average, analysts predict that Warner Chilcott will post $3.28 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Susquehanna initiated coverage on shares of Warner Chilcott in a research note to investors on Tuesday. They set a “positive” rating and a $19.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Warner Chilcott from an “outperform” rating to a “neutral” rating in a research note to investors on Monday, March 18th. They now have a $15.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Warner Chilcott in a research note to investors on Monday, February 25th. They now have a $16.00 price target on the stock, up previously from $15.00.
One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. Warner Chilcott currently has a consensus rating of “Buy” and a consensus target price of $18.56.
Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America.